Ekso Bionics Holdings, Inc. (EKSO)
| Market Cap | 65.43M |
| Revenue (ttm) | 9.33M |
| Net Income (ttm) | -16.96M |
| Shares Out | 10.75M |
| EPS (ttm) | -2.02 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 14 |
| Last Price | $5.18 |
| Previous Close | $5.02 |
| Change ($) | 0.16 |
| Change (%) | 3.19% |
| Day's Open | 5.05 |
| Day's Range | 5.05 - 5.33 |
| Day's Volume | 94,683 |
| 52-Week Range | 2.83 - 14.98 |
Ekso Bionics (EKSO) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
BLKB, CTXS, EKSO, FHI, and GCI have been added to the Zacks Rank #5 (Strong Sell) List on May 5, 2021
Shares of Ekso Bionics Holdings (NASDAQ:EKSO) increased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 22.73% year over year to ($0.34), which m...
RICHMOND, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today report...
Ekso Bionics (EKSO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
RICHMOND, Calif., April 22, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will...
Ekso Bionics (EKSO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the ...
RICHMOND, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announ...
Shares of Ekso Bionics Holdings (NASDAQ:EKSO) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 1100.00% over the past year to ($0.48), w...
On Thursday, February 25, Ekso Bionics Holdings (NASDAQ:EKSO) will report its last quarter's earnings. Here is Benzinga's preview of the company's release.
RICHMOND, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will ...
RICHMOND, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics”), an industry leader in exoskeleton technology for medical and industrial use, today announ...
Ekso Bionics Holdings Inc (NASDAQ: EKSO) has increased the size of the previously announced public offering to 3.9 million common shares at $10.25 per share, raising around $40 million in gross proceeds...
RICHMOND, Calif., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics”), an industry leader in exoskeleton technology for medical and industrial use, today announ...
RICHMOND, Calif., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics”), an industry leader in exoskeleton technology for medical and industrial use, today announ...
Science fiction collides with reality, as exoskeletons become a real-world device with a number of applications. The post 2 Science-Fiction Stocks to Play This Emerging Megatrend appeared first on Inves...
RICHMOND, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced preliminary t...
RICHMOND, Calif., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announc...
RICHMOND, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announc...
Ekso Bionics Holdings, Inc. (EKSO) CEO Jack Peurach on Q3 2020 Results - Earnings Call Transcript
RICHMOND, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reporte...
A c utting-edge endurance-boosting assistive device , E VO is designed to reduce the risk of repetitive or fatigue-related injuries for construction workers and other industrial employees
RICHMOND, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will ...
RICHMOND, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that Jack ...
RICHMOND, Calif., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”) , an industry leader in exoskeleton technology for medical and industrial use, today un...
Ekso Bionics Holdings, Inc. (EKSO) CEO Jack Peurach on Q2 2020 Results - Earnings Call Transcript
Ekso Bionics (EKSO) delivered earnings and revenue surprises of 0.00% and 22.38%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Ekso Bionics (EKSO) Q2 earnings are expected to have been boosted by its recent efforts to grow virtual connectivity with customers and to reduce costs.
RICHMOND, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that it wil...
WASHINGTON and RICHMOND, Calif., July 09, 2020 (GLOBE NEWSWIRE) -- The Army Distaff Foundation (ADF) , a non-profit charity in Washington, D.C., which operates Knollwood Military Life Plan Community...
Ekso Bionics Holdings (NASDAQ: EKSO) shares were trading higher Friday on continued strength after the company received FDA clearance to market its EksoNR robotic exoskeleton.
Ekso Bionics (EKSO) news for Thursday concerning approval from the FDA for one of its devices has EKSO stock soaring higher.
Shares of Ekso Bionics Holdings Inc. EKSO, 130.85% soared Thursday, after the company said it has received 501 clearance from the U.S. Food and Drug Administration to market its EksoNR robotic exoskelet...
RICHMOND, Calif., June 25, 2020 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”) , an industry leader in exoskeleton technology for medical and industrial use, today ann...
Ekso Bionics (EKSO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
RICHMOND, Calif., June 10, 2020 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today annou...
RICHMOND, Calif., June 08, 2020 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today annou...
Annual Awards Program Recognizes Outstanding Health & Medical Technology Products and Companies Annual Awards Program Recognizes Outstanding Health & Medical Technology Products and Companies
RICHMOND, Calif., May 20, 2020 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today report...
Wall Street sell-side analysts are positive about Ekso Bionics Holdings Inc (NASDAQ:EKSO) and Entasis Therapeutics Holdings Inc (NASDAQ:ETTX), even though their holdings have lost more than 59% over the...
Ekso Bionics Holdings, Inc. (EKSO) CEO Jack Peurach on Q1 2020 Results - Earnings Call Transcript
- Company Regains Nasdaq Listing Compliance -
RICHMOND, Calif., March 24, 2020 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (the “Company”) (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced tha...
Ekso Bionics Holdings, Inc. (EKSO) CEO Jack Peurach on Q4 2019 Results - Earnings Call Transcript
RICHMOND, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced a collaboration with...
RICHMOND, Calif., Dec. 20, 2019 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today annou...
RICHMOND, Calif., Dec. 20, 2019 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced it signed a distribu...
RICHMOND, Calif., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today annou...
Ekso Bionics Holdings Inc. (EKSO) CEO Jack Peurach on Q3 2019 Results - Earnings Call Transcript
RICHMOND, Calif., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced that Jack Peurach, ...
About EKSO
Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the United States and internationally. The company operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, sells, and rents exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, sells, and rents exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. Ekso Bionics Holdings, Inc. has a license agreement ... [Read more...]
| Industry Medical Instruments & Supplies | Founded 2005 |
| CEO Nathan Harding | Employees 39 |
| Stock Exchange NASDAQ | Ticker Symbol EKSO |
Financial Performance
In 2020, EKSO's revenue was $8.88 million, a decrease of -36.18% compared to the previous year's $13.92 million. Losses were -$15.83 million, 30.4% more than in 2019.
Analyst Forecasts
According to 2 analysts, the average rating for EKSO stock is "Buy." The 12-month stock price forecast is 10.00, which is an increase of 93.05% from the latest price.